| Literature DB >> 25464832 |
Tokiko Watanabe1, Eiryo Kawakami2, Jason E Shoemaker1, Tiago J S Lopes2, Yukiko Matsuoka3, Yuriko Tomita2, Hiroko Kozuka-Hata4, Takeo Gorai5, Tomoko Kuwahara6, Eiji Takeda6, Atsushi Nagata6, Ryo Takano6, Maki Kiso6, Makoto Yamashita6, Yuko Sakai-Tagawa6, Hiroaki Katsura6, Naoki Nonaka6, Hiroko Fujii6, Ken Fujii2, Yukihiko Sugita6, Takeshi Noda6, Hideo Goto6, Satoshi Fukuyama1, Shinji Watanabe7, Gabriele Neumann8, Masaaki Oyama4, Hiroaki Kitano9, Yoshihiro Kawaoka10.
Abstract
Host factors required for viral replication are ideal drug targets because they are less likely than viral proteins to mutate under drug-mediated selective pressure. Although genome-wide screens have identified host proteins involved in influenza virus replication, limited mechanistic understanding of how these factors affect influenza has hindered potential drug development. We conducted a systematic analysis to identify and validate host factors that associate with influenza virus proteins and affect viral replication. After identifying over 1,000 host factors that coimmunoprecipitate with specific viral proteins, we generated a network of virus-host protein interactions based on the stage of the viral life cycle affected upon host factor downregulation. Using compounds that inhibit these host factors, we validated several proteins, notably Golgi-specific brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1) and JAK1, as potential antiviral drug targets. Thus, virus-host interactome screens are powerful strategies to identify targetable host factors and guide antiviral drug development.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25464832 PMCID: PMC4451456 DOI: 10.1016/j.chom.2014.11.002
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 21.023